BioNeex, a NYC-based provider of a business development platform for research and development (R&D) in the biopharmaceutical industry, has raised $500K seed funding round.
Leaders in the biopharma sector, including former Pfizer and Amgen executives, led the funding round.
With the money, the company hopes to improve the BioNeex platform members’ user experience in addition to developing new products.
“Their investment in BioNeex will help us continue to provide new products, services and platform enhancements that improve how drug development companies, potential partners and investors interact via the BioNeex marketplace.”
Smbat Rafayelyan, founder & CEO
For the biopharmaceutical sector, BioNeex offers an R&D business development platform. This is a marketplace where biotech and biopharma companies, as well as venture capital firms, come together to directly facilitate investment deals and co-development partnerships and licensing for preclinical and clinical-stage drug candidates.
Potential investors, co-development partners, and license holders can get the most recent data from drug candidate developers through BioNeex and get in touch with them directly.
